David Johnson

David brings 30 years of commercial and operational experience and currently serves as chief commercial officer of Global Blood Therapeutics where he leads the global commercial functions that he built and which facilitated the launch of Oxbryta® in 2019. Previously, he spent 15 years at Gilead Sciences, Inc., where he held roles of increasing responsibility in the company’s commercial organization. Most recently, he served as vice president, sales and marketing, Liver Disease Business Unit, where he was instrumental in building and leading the company’s liver disease franchise, including launching four medicines for hepatitis. Prior to that, David led the Antiviral Business Unit, where he helped launch and oversee the HIV franchise. Before Gilead, he had an 11-year tenure at GlaxoSmithKline, where he held various positions in sales, product marketing, business development, global commercial strategy, and portfolio development. David earned an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina and a B.A. in Business Marketing from the University of Puget Sound.